Symposium on Gorlin Syndrome, Nevoid Basal Cell Carcinoma and Basal Cell Carcinoma Syndrome, Society for Investigative Dermatology Annual Meeting 2005, St. Louis, MO: “Molecular Approaches to Diagnosis of the Nevoid Basal Cell Carcinoma Syndrome”
Association for Molecular Pathology, Orlando, FL, 2006 Annual Meeting: “Patent Law and Genes”
H. Lee Moffitt Cancer & Research Institute, Division of Hematopathology and Laboratory Medicine, April 2007, Tampa FL: “SDHD and SDHB mutations in malignant paragangliomas”
H. Lee Moffitt Cancer Center and Research Institute/USF College of Medicine Second Annual Cutaneous Lymphoma Symposium 2008, Lake Buena Vista, FL: “Molecular Pathology Role in Early & Late CTCL and PTCLs” and “Molecular Pathology and Applications in Dx and Management of Cutaneous Lymphomas – B and T Cell Type”
University of South Florida College of Medicine, Eighth Annual Symposium on Bioethics 2008, Tampa, FL: Panelist, Bioethics and Genomics, in “Medical Ethics in the University Community: A Potpourri”
H. Lee Moffitt Cancer Center and Research Institute/USF College of Medicine Second Annual Total Cancer Care Summit 2008, San Juan, Puerto Rico: Chairperson, “Current State-of-the-Art Diagnostics”
Emory University School of Medicine, Department of Genetics Grand Rounds, January 2009, Atlanta, GA: “Gene Patents and Genetic Testing in the United States”
Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) Genetic and Genomic Testing, February 2009, Baltimore, MD: Comments on behalf of the Association for Molecular Pathology
Association for Molecular Pathology, Molecular Genetic Pathology Review Course, May 2009, Rockville, MD: “Laboratory Regulation and Management” and “Molecular Coagulation”
Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) Screening Genetic Tests, May 2009, Baltimore, MD: Comments on behalf of the Association for Molecular Pathology
Association for Molecular Pathology, 2009 Annual Meeting, November 2009, Orlando, FL: Panelist, “Gene Patents: The Current Environment and How We Got Here”
Institute of Medicine, Roundtable on Translating Genomic-Based Research for Health, Evidence Generation for Genomic Diagnostic Test Development: A Workshop, November 2010, Washington, D.C.: Moderator, “Evidence, Assessing stakeholder perspectives on evidence, illustrated through case examples,” and Panelist, “Strategies for Moving Forward, A discussion of potential next steps”
United States & Canadian Academy of Pathology, American Society for Clinical Pathology Joint Companion Society Meeting with Association for Molecular Pathology, February 2011, San Antonio, TX: Panelist,“Gene Patents: The Future Gene Research in an Era of Patents – Scientific and Legal Considerations,” presentation, “The Legal History of Gene Patents”
CHI Next Generation Dx Summit, August 2011, Washington, D.C.: “Products or Services? IVDs, LDTs, and Regulatory Compliance on the Road to Personalized Patient Care”
Beaumont 10th Annual Symposium on Molecular Pathology, Clinical Applications of Genomic Medicine, September, 2011, Troy, MI: “Gene Patents and Personalized Medicine”
American Society for Clinical Pathology (ASCP), 2011 Annual Meeting, October 2011, Las Vegas, NV: Panelist, “Gene Patents – Scientific and Legal considerations,” Presentation, “The Legal History of Gene Patents”
Association for Molecular Pathology, 2011Annual Meeting, November 2011, Grapevine, TX: Panelist, “2012 Molecular CPT Coding Structure for Oncology and Genetics Testing Reveals (almost) All!”
Genetic Alliance, Genetic Testing and Data Management Summit, Improving Health Outcomes, Disease Management, and Accountable Care Delivery, March, 2012, Washington, D.C.: Panelist, “Evidence”
American Society of Clinical Oncology (ASCO), 2012 Annual Meeting, June 2012, Chicago, IL: Panelist, “Gene Patenting: Effects on Biotechnology and Oncology,” Presentation, “Current Status of Court Decisions on Gene Patents and Impact of Diagnostic Testing”
Cleveland Clinic Foundation, Pathology Grand Rounds, September 20, 2012, Cleveland, OH: “Gene Patents and Personalized Medicine”
CHI Evidence-Based Reimbursement Summit, November 2012, Philadelphia, PA: “Coding and Reimbursement for Molecular Testing: New Developments and Interesting Times Ahead”
United States Patent and Trademark Office (USPTO), January 2013, Alexandria, VA: Participant, “Roundtable on Genetic Diagnostic Testing”
CHI Molecular Med Tri-Con, February 2013, San Francisco, CA: “May You Live in Interesting Times: The Evolving Landscape of CPT Coding for Molecular Testing”
National Coalition for Cancer Survivorship Cancer Policy Roundtable, March 2013, Washington, D.C.: Panelist, “FDA: Challenges to Protecting Public Health and New Initiatives in Drug Review”
Clinical Laboratory Standards Institute (CLSI) Leadership Conference and Educational Symposium, March 2013, Arlington, VA: “Educational Symposium Part 1, Embracing Molecular Diagnostics and Genome Sequencing, ‘Molecular and Genome Sequencing from a Laboratory Perspective’”
Association for Molecular Pathology (AMP) Webinar, April 2013: Moderator, “Association for Molecular Pathology v. Myriad Genetics, Inc.”
Cancer Leadership Council, May 2013, Washington, D.C.: “Can Human Genes Be Patented? A discussion of the Myriad case”
Breast Cancer Action Webinar, June 2013: “The Supreme Court Decision to Overturn Gene Patents: What it Means for you”
Association for Molecular Pathology (AMP) Webinar, June 2013: “Association for Molecular Pathology v. Myriad Genetics, Inc.”
Congressional Briefing, July 2013, Washington, D.C.: Panelist, “Supreme Court Strikes Down Patents on Human Genes: Implications for Patients and Personalized Medicine”
CHI Next Generation Dx Summit, August 2013, Washington, D.C.: Organizer, Speaker, and Moderator “Gene Patents: AMP vs. Myriad, What Are the Commercial Implications?”
Clinical Laboratory Management Association (CLMA), St. Louis Chapter, Molecular Diagnostics Seminar, October 2013, St. Louis, Mo: “The Evolving Landscape of CPT Coding for Molecular Testing”
CHI Evidence-Based Reimbursement Summit, October 2013, Washington, D.C.: “CPT Codes for Multigene Testing Using Next-Generation Sequencing: Opportunities and Challenges Ahead”
JP Morgan Healthcare Conference, January 2014, San Francisco, CA: Panelist, “Supreme Court Strikes Down Patents on Human Genes: Implications for Industry, Pricing & Personalized Medicine”
Cleveland Clinic, Pathology and Laboratory Medicine Institute Fifth Annual Education Conference “The Laboratory of the Future,” April 2014, Cleveland OH: “Gene Patents Personalized Medicine: Current and Future Perspectives”
AdvaMed, Diagnostics Payment Work Group Quarterly Meeting, May 2014, Guest Speaker, “AMP Policy Issues and Impact of ‘PAMA’ Legislation on Clinical Practice”
Association for Molecular Pathology (AMP) Webinar, May 2014: Moderator, “AMP 2014 Annual Meeting Advocacy Day: What to Expect and How to Participate”
Clinical Laboratory Management Association (CLMA) Webinar, June 2014: Patient Access to Laboratory Test Reports: Cleveland Clinic Approach
Centers for Medicare & Medicaid Services, Clinical Laboratory Fee Schedule Public Meeting, July 2014, Baltimore, MD: Protecting Access to Medicare Act of 2014 “Improving Medicare Policies for Clinical Diagnostic Laboratory Tests,” Association for Molecular Pathology, Public Comments
National Commission on Forensic Science, Third Meeting, August 2014, Washington, D.C.: Speaker and Panelist for session, “The Role of Accreditation in Forensic Science,” “Accreditation in the Clinical Arena”
Association for Molecular Pathology (AMP) Webinar, September 2014: “FDA Laboratory Developed Test (LDT) Draft Guidance and the Potential Impact on Clinical Practice”
Association for Molecular Pathology (AMP) Webinar, November 2014: Moderator, “AMP 2014 Annual Meeting Advocacy Day: What to Expect When Meeting with Your Legislator”
Association for Molecular Pathology 2014 Annual Meeting, Reference Material Forum November 2014, Washington, D.C., “Reference Materials in the Context of FDA’s Draft Guidance for Oversight of LDPs”
Association for Molecular Pathology 2014 Annual Meeting, November 2014, Washington, D.C., Congressional Briefing, Panelist, “Realizing the Dream of Precision Medicine by Preserving Access to Innovative High Quality Tests”
Association for Molecular Pathology 2014 Annual Meeting, November 2014, Washington, D.C.: Moderator, “Framework for Oversight of LDTs: A Conversation with FDA”
Association for Molecular Pathology 2014 Annual Meeting, November 2014, Washington, D.C., Congressional Briefing, Panelist, “AMP Advocacy Day & NGS Microcosting and Health Economic Modeling Project Updates”
American Medical Association CPT and RBRVS 2015 Annual Symposium, November 2014, Chicago, IL, “Molecular Pathology”
Food and Drug Administration, Public Workshop – Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs), January 8-9, 2015, Bethesda, MD, Panelist, Categories for Continued Enforcement Discretion
Food and Drug Administration, Public Workshop – Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs), January 8-9, 2015, Bethesda, MD, Two presentations on behalf of Association for Molecular Pathology, Categories for Continued Enforcement Discretion and Quality Systems Regulation
Food and Drug Administration, Public Workshop – Optimizing FDA’s Regulatory Oversight of Next Generation Sequencing Diagnostic Tests, February 20, 2015, Bethesda, MD, Presentation on behalf of Association for Molecular Pathology
Yale School of Medicine, Department of Laboratory Medicine, Research Seminar/Grand Rounds, March 25, 2015, New Haven, CT, “Association for Molecular Pathology v. Myriad Genetics: The Supreme Court Gives a Win to Personalized Medicine”
10th Annual CITI at Cleveland Clinic, March 31, 2015. Cleveland, OH, “Changes in Regulation of Laboratory Developed Tests: Potential Commercial Impacts”
Cleveland Clinic, Advances in Lung Cancer: A Multidisciplinary Approach, April 2015: “Tissue Requirements and Molecular Testing for EGFR and ALK in NSCLC”
CHI Next Generation Dx Summit, August 2015, Washington, D.C.: “Precision Medicine – Challenges Associated with Annotation and Interpretation of Somatic Mutation Data”
CHI Next Generation Dx Summit, August 2015, Washington, D.C.: Regulatory Panel, “Challenges and Prospects Ahead for LDTs”
CHI Next Generation Dx Summit, August 2015, Washington, D.C.: Moderator, Problem-Solving Breakout Discussion, “Protecting Access To Medicare Act Of 2014 (PAMA): What Do These New Regulations Mean For Stakeholders?”
South Carolina Society of Pathologists 2015 Annual Meeting, September 2015, Ashville, NC: Gordon R. Hennigar Lecture: Dialogues in Pathology, Evidence Based Pathology, Speaker “Applications of Immunohistochemistry and Molecular Pathology,” and Roundtable Discussion Panelist
Beaumont Health System 24th Annual Symposium on Molecular Pathology, September 2015, Troy, MI: “FDA Regulation of Laboratory Developed Tests”
Avalere Health Webinar, September 2015: “FDA’s Regulation Of Laboratory Developed Tests, Where Do We Go Next”
Cleveland Clinic Laboratories, Association for Molecular Pathology 2015 Annual Meeting, “Molecular Testing in NSCLC: The Cleveland Clinic Approach,” November 2015, Washington, D.C.
Association for Molecular Pathology 2015 Annual Meeting, “Twitter 101: Social Media Benefits for the Molecular Professional,” November 2015, Washington, D.C., Presenter and Panelist
Association for Molecular Pathology 2015 Annual Meeting, “Modernization of CLIA Regulations for Laboratory Developed Testing Procedures (LDPs): An Update from Washington,” Speaker, “Overview of AMP’s Proposal for Modernization of CLIA Regulations for LDPs” and Moderator, November 2015, Washington, D.C.
Association for Molecular Pathology 2015 Annual Meeting, “AMP Early Career Luncheon: AMP Professional Relations Committee,” November 2015, Washington, D.C., Presenter and Panelist
JP Morgan Analyst Call, Speaker, “The Regulatory Landscape for Lab Developed Tests: Discussions of Change, What to Expect?” November, 2015
Cleveland Clinic, Taussig Cancer Center, Tumor Board (Online CME), “Current and Future Treatment Options for Melanoma,” Presenter and Panelist, January 2016
Cleveland Clinic, Taussig Cancer Center, Tumor Board (Online CME), “Current Issues in the Management of Non–Small Cell Lung Cancer: Treatment of ALK-Positive Disease and Use of Stereotactic Body Radiotherapy in Oligometastatic Lung Cancer,” Presenter and Panelist, February 2016
Food and Drug Administration, Public Workshop – Next Generation Sequencing-Based Oncology Panels,” February 25, 2016, Bethesda, MD, Presentation on behalf of Association for Molecular Pathology
11th Annual CITI at Cleveland Clinic, March 1, 2016, Cleveland, OH, “Molecular Pathology: Trends in Regulation, Reimbursement and Technologies. What Does the Future Hold?”
CHI Molecular Med Tri-Con, March 2016, San Francisco, CA: “Who Should Regulate Cancer NGS Tests: FDA, CMS/CLIA, or Both”
University of New Mexico, Pathology Seminar Series, April 2016, Albuquerque, NM: “FDA, CMS and the Oversight of Laboratory Developed Tests”
Arizona State University, Sandra Day O’Connor College of Law, April, 2016, Phoenix, AZ, Workshop Participant: “Regulatory and Reimbursement Obstacles and Drivers for Clinical Uptake of Molecular Diagnostics”
CHI Next Generation Dx Summit, August 2016, Washington, D.C.: Session Chair, PAMA Reflections; Speaker, “PAMA: The Final Rule is Out – What Does it Mean for Labs”
CHI Next Generation Dx Summit, August 2016, Washington, D.C.: “Precision Medicine – Challenges Associated with Annotation and Interpretation of Somatic Mutation Data”; Panelist, “Incidentalome in Genomic Medicine: An Obstacle or a Driver”
Illumina Next Generation Sequencing in the Clinic Seminar, September 2016, Chicago, IL: “Dynamics of Variant Interpretations from NGS Samples”
Clinical Laboratory Improvement Advisory Committee, November 2016, Atlanta, GA: “Autopsies as a Quality Assurance Tool”
Association for Molecular Pathology 2016 Annual Meeting, “AMP v. Myriad: 3 Years Later,” Presenter and Panelist, November 2016, Charlotte, NC
Association for Molecular Pathology 2016 Annual Meeting, “Operationalizing PAMA Data Collection and Reporting at Your Institution,” Presenter and Panelist, November 2016, Charlotte, NC
Association for Molecular Pathology 2016 Annual Meeting, “Patient Access to Clinical Laboratory Testing Information,” Moderator, November 2016, Charlotte, NC
GenomeWeb webinar, “Roundtable Discussion: Best Practices for Validation, Monitoring, and Controls,” panelist and presenter on “Validation of tumor profiling NGS Procedures,” March 2017
McDermott+Consulting (3rd Annual) +Dx Diagnostics Forum 2017, Washington, D.C., “Update on Payment for Clinical Diagnostic Laboratory Tests,” panelist, April 2017
LabRoots’ 2nd Annual Molecular Diagnostics Virtual Conference, “PAMA: The First Reporting Period is Over. What Does This Legislation Mean for Laboratories,” April 2017
Arizona State University Sandra Day O’Connor College of Law, Phoenix, AZ, “6th Annual Roundtable Workshop on Regulation and Reimbursement of Molecular Diagnostics,” speaker, “Implementation of the Clinical Laboratory Provisions of the Protecting Access to Medicare Act of 2014 (PAMA),” April 2017
Clinical Laboratory Improvement Advisory Committee, November 2016, Atlanta, GA: “Pathologists as Integral Care Team Members”
Association for Molecular Pathology 2017 Annual Meeting, “What is the Legal Risk for Interpreting and Classifying Sequencing Variants in the Laboratory?” Moderator, November 2017, Salt Lake City, UT
LabRoots’ 3nd Annual Molecular Diagnostics Virtual Conference, “Medicare’s New National Coverage Determination for Next Generation Sequencing: What Does it Mean for Diagnostic Laboratories?” April 2018
Arizona State University Sandra Day O’Connor College of Law, Phoenix, AZ, “7th Annual Roundtable Workshop on Regulation and Reimbursement of Molecular Diagnostics,” speaker, “National Coverage Determination for Next Generation Sequencing,” April 2018
American Society of Clinical Oncology (ASCO), 2018 Annual Meeting, Chicago, IL, Pre-Annual Meeting Educational Program, “New Drugs in Oncology,” Keynote Lecture: Next Generation Sequencing – Drug Development and Drug Treatment, The New Era of Drug Development in the Clinic,” June 2018
Arizona State University Sandra Day O’Connor College of Law, Phoenix, AZ, “8th Annual Roundtable Workshop on Regulation and Reimbursement of Molecular Diagnostics,” speaker, “Hot Issues! in Clinical Laboratory Reimbursement,” April 2019
CHI Next Generation Dx Summit, Washington, D.C.: Session Chair, “Regulation of Dx: Where Do We Go From Here?”; Moderator, “Regulation and Policy for Diagnostic Tests – Enhancing or Restricting the Innovation and Progress In Diagnostics?”, August 2019
CHI Next Generation DX Summit, Washington, D.C., Session Chair, “Featured Interactive Session: A Business Case Study on Genomic Health,” August 2019
South Carolina Society of Pathologists 2019 Annual Meeting, Asheville, NC, Gordon R. Hennigar Lecture: “Evidence-Based Medicine and Precision Medicine” and “Next Generation Sequencing and Targeted Therapies,” September 2019
Northern Illinois Law School, Federalist Society Chapter, DeKalb, IL, “Debate on Medicare for All” with Adam Broad, Illinois Single Payer Coalition, September 2019
Association for Molecular Pathology 2019 Annual Meeting, Baltimore, MD, Moderator, “The Future of the AMP v. Myriad Decision: Exploring Potential Impacts on Multigene Panel Testing and Patient Care,” November 2019
Association for Molecular Pathology 2019 Annual Meeting, Baltimore, MD, Presenter, “AMP Solid Tumors Subdivision Open Forum,” November 2019
Quinnipiac Law School, Federalist Society Chapter, North Haven, CT, “E-Cigarettes, Are They Safer Than Conventional Cigarettes,” January 2020
Federalist Society, Regulatory Transparency Project, Panelist, Deep Dive Episode 98 – “Regulatory Reforms and COVID Pandemic,” March 2020
Heartland Institute, Panelist, “Return to Normal: Getting Our States Back to Work Quickly and Safely,” April 2020
Federalist Society, Regulatory Transparency Project, Narrator, “FDA Regulation of Diagnostic Testing and COVID-19” May 2020
University of Arizona Law School, Speaker, “An Explainer: Regulation of Diagnostic Tests,” May 2020 (https://law.arizona.edu/covid-19-health-law-resources)
Cato Institute, Panelist, “COVID-19 and the Right to Test,” June 2020
Federalist Society, COVID-19 & the Law Conference, Panelist, “Regulation or ‘Don’t Let a Good Crisis Go to Waste,” June 2020
Federalist Society, Regulatory Transparency Project, Deep Dive Episode 117 – “How to Approach Data Collection and Breaches in the Age of COVID-19,” June 2020
Competitive Enterprise Institute, Panelist, “Repeal for Resilience: Did Over-Regulation Cause America’s COVID Testing Delay?” July 2020
CHI Next Generation Dx Summit Virtual, Washington, D.C., Moderator, “Investment Landscape and Opportunity for Diagnostic Tests,” August 2020
Association for Molecular Pathology 2020 Annual Meeting, Virtual: Moderator, “Distributed Laboratories and Third-Party Interpretation Services, ” November 2020